Cargando…

Dosimetric Predictors of Toxicity after Prostate Stereotactic Body Radiotherapy: A Single-Institutional Experience of 145 Patients

The indications for stereotactic body radiotherapy (SBRT) for prostate cancer have increased. However, the relationships between adverse events and risk factors remain unclear. This study aimed to clarify associations between adverse events and dose index for prostate SBRT. Participants comprised 14...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fujii, Kyohei, Nakano, Masahiro, Kawakami, Shogo, Tanaka, Yuichi, Kainuma, Takuro, Tsumura, Hideyasu, Tabata, Ken-ichi, Satoh, Takefumi, Iwamura, Masatsugu, Ishiyama, Hiromichi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10217554/ https://www.ncbi.nlm.nih.gov/pubmed/37232841 http://dx.doi.org/10.3390/curroncol30050383

Ejemplares similares

A phase I dose-escalation trial of stereotactic body radiotherapy using 4 fractions for patients with localized prostate cancer
por: Kainuma, Takuro, et al.
Publicado: (2019)

A cold spot compensation technique using a combination of trans-rectal ultrasonography and intraoperative computed tomography for interstitial permanent prostate brachytherapy: a single-arm prospective trial
por: Ishiyama, Hiromichi, et al.
Publicado: (2018)

Comparison of prostate contours between conventional stepping transverse imaging and Twister-based sagittal imaging in permanent interstitial prostate brachytherapy
por: Kawakami, Shogo, et al.
Publicado: (2017)

Dosimetry of permanent interstitial prostate brachytherapy for an interoperative procedure, using O-arm based CT and TRUS
por: Ishiyama, Hiromichi, et al.
Publicado: (2016)

(125)Iodine monotherapy for Japanese men with low- and intermediate-risk prostate cancer: outcomes after 5 years of follow-up
por: Sekiguchi, Akane, et al.
Publicado: (2014)

Comparison of three different techniques of low-dose-rate seed implantation for prostate cancer
por: Ishiyama, Hiromichi, et al.
Publicado: (2015)

A phase II trial of stereotactic body radiotherapy in 4 fractions for patients with localized prostate cancer
por: Kawakami, S., et al.
Publicado: (2022)

Perioperative Search for Circulating Tumor Cells in Patients Undergoing Prostate Brachytherapy for Clinically Nonmetastatic Prostate Cancer
por: Tsumura, Hideyasu, et al.
Publicado: (2017)

Prostate-specific antigen nadir after high-dose-rate brachytherapy predicts long-term survival outcomes in high-risk prostate cancer
por: Tsumura, Hideyasu, et al.
Publicado: (2016)

Dosimetric factors associated with long-term patient-reported outcomes after definitive radiotherapy of patients with head and neck cancer
por: Hayakawa, Toyokazu, et al.
Publicado: (2019)

Quality of life score as a prognosticator for pharyngeal cancer patients treated with radiotherapy
por: Ishiyama, Hiromichi, et al.
Publicado: (2022)

High-dose-rate brachytherapy and hypofractionated external beam radiotherapy combined with long-term hormonal therapy for high-risk and very high-risk prostate cancer: outcomes after 5-year follow-up
por: Ishiyama, Hiromichi, et al.
Publicado: (2014)

Radiotherapy for Oligometastases and Oligo-Recurrence of Bone in Prostate Cancer
por: Tabata, Ken-ichi, et al.
Publicado: (2012)

Effect of cisplatin on metastatic castration-resistant prostate cancer with BRCA2 mutation: A case report
por: Koguchi, Dai, et al.
Publicado: (2021)

Cytopathic effects and local immune responses in repeated neoadjuvant HSV-tk + ganciclovir gene therapy for prostate cancer
por: Yanagisawa, Nobuyuki, et al.
Publicado: (2021)

Catheter displacement prior to the delivery of high-dose-rate brachytherapy in the treatment of prostate cancer patients
por: Kawakami, Shogo, et al.
Publicado: (2014)

Direct comparison of low-dose-rate brachytherapy versus radical prostatectomy using the surgical definition of biochemical recurrence for patients with intermediate-risk prostate cancer
por: Tsumura, Hideyasu, et al.
Publicado: (2022)

Comparative effectiveness of low-dose-rate brachytherapy with or without external beam radiotherapy in favorable and unfavorable intermediate-risk prostate cancer
por: Tsumura, Hideyasu, et al.
Publicado: (2022)

A high neutrophil-to-lymphocyte ratio is a poor prognostic factor for castration-resistant prostate cancer patients who undergo abiraterone acetate or enzalutamide treatment
por: Kawahara, Takashi, et al.
Publicado: (2020)

Prognostic Value of the LATITUDE and CHAARTED Risk Criteria for Predicting the Survival of Men with Bone Metastatic Hormone-Naïve Prostate Cancer Treated with Combined Androgen Blockade Therapy: Real-World Data from a Japanese Multi-Institutional Study
por: Kawahara, Takashi, et al.
Publicado: (2020)

A novel prognostic model for Japanese patients with newly diagnosed bone‐metastatic hormone‐naïve prostate cancer
por: Miyoshi, Yasuhide, et al.
Publicado: (2020)

Membranous Expression of Heart Development Protein with EGF-like Domain 1 Is Associated with a Good Prognosis in Patients with Bladder Cancer
por: Mori, Kohei, et al.
Publicado: (2023)

Development and validation of a survival nomogram and calculator for male patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate and/or enzalutamide
por: Kawahara, Takashi, et al.
Publicado: (2023)

Dosimetric characterization of Elekta stereotactic cones
por: Borzov, Egor, et al.
Publicado: (2017)

Dosimetric comparison of carbon ion radiotherapy and stereotactic body radiotherapy with photon beams for the treatment of hepatocellular carcinoma
por: Abe, Takanori, et al.
Publicado: (2015)

Dosimetric Evaluation and Optimization of Fractionated Stereotactic Radio-Surgery
por: Chougule, Arun
Publicado: (2018)

Dosimetric comparison of different treatment modalities for stereotactic radiotherapy
por: Hsu, Shih-Ming, et al.
Publicado: (2017)

Complete biochemical response following metastasis-directed radiotherapy for oligometastatic prostate cancer: A case report
por: Okuda, Satoshi, et al.
Publicado: (2020)

Nestin Is an Independent Predictor of Cancer-Specific Survival after Radical Cystectomy in Patients with Urothelial Carcinoma of the Bladder
por: Tabata, Ken-ichi, et al.
Publicado: (2014)

Dosimetric comparison of linear accelerator-based stereotactic radiosurgery systems
por: Sharma, S. D., et al.
Publicado: (2007)

The impact of emphysema on dosimetric parameters for stereotactic body radiotherapy of the lung
por: Ochiai, Satoru, et al.
Publicado: (2016)

Assessment of biological dosimetric margin for stereotactic body radiation therapy
por: Kawahara, Daisuke, et al.
Publicado: (2020)

Multi-institutional retrospective analysis of ultrahypofractionated radiotherapy for Japanese prostate cancer patients
por: Ishiyama, Hiromichi, et al.
Publicado: (2021)

Dosimetric effect of rotational setup errors in stereotactic radiosurgery with HyperArc for single and multiple brain metastases
por: Sagawa, Tomohiro, et al.
Publicado: (2019)

Efficacy and safety of apalutamide in Japanese patients with nonmetastatic castration-resistant prostate cancer: a subgroup analysis of a randomized, double-blind, placebo-controlled, Phase-3 study
por: Uemura, Hiroji, et al.
Publicado: (2020)

Dosimetric comparison of CT-guided iodine-125 seed stereotactic brachytherapy and stereotactic body radiation therapy in the treatment of NSCLC
por: Li, Ranran, et al.
Publicado: (2017)

The dosimetric impact of implants on the spinal cord dose during stereotactic body radiotherapy
por: Yazici, Gozde, et al.
Publicado: (2016)

Dosimetric characteristics of the small diameter BrainLab™ cones used for stereotactic radiosurgery
por: Khelashvili, Gocha, et al.
Publicado: (2012)

Comparison of four techniques for spine stereotactic body radiotherapy: Dosimetric and efficiency analysis
por: Aljabab, Saif, et al.
Publicado: (2018)

Dosimetric performance of the new high‐definition multileaf collimator for intracranial stereotactic radiosurgery
por: Dhabaan, Anees, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_1gneplppeh0kf3i14j3sag1c1p